Clinical Trial Update: Immunotherapy Based on Antigen-specific Immune Effector Cells Targeting Neurofibromatosis or Schwannomatosis [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update for an immunotherapy using antigen-specific immune effector cells targeting neurofibromatosis or schwannomatosis in cancer patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Antigen-specific immune effector cells immunotherapy

Snippet

Sponsor: Shenzhen Geno-Immune Medical Institute | Conditions: Cancer | Phase 1, Phase 2 | Status: UNKNOWN